Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Ingrid A BeckCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0001-7438-3209
Ceejay L BoyceCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0002-3716-8216
Marley D BishopCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0009-0007-1552-5562
Alyssa R OldroydCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.ORCID 0000-0002-0664-4427
Louise du ToitDepartment of Immunology, University of Pretoria, Pretoria, South Africa.ORCID 0000-0002-6355-6095
Amashnee SaimenDepartment of Immunology, University of Pretoria, Pretoria, South Africa.
Kholofelo Mn RamaropeDepartment of Immunology, University of Pretoria, Pretoria, South Africa.
Sonia HitchcockDepartment of Immunology, University of Pretoria, Pretoria, South Africa.ORCID 0000-0002-4717-3617
Nicolette M du PlessisDepartment of Immunology, University of Pretoria, Pretoria, South Africa.ORCID 0000-0002-9009-691X
Loice MbogoUniversity of Washington Global Assistance Program-Kenya, Nairobi, Kenya.
Bhavna H ChohanDepartments of Global Health, Medicine, Pediatrics, and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-2125-6799
Pooja MaheriaDepartment of Medicine - Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0009-0003-8462-9323
Patrick OyaroHealth Innovations Kenya, Kisumu, Kenya.
Kevin KnowlesFrontier Science, Amherst, New York, USA.
Zhongli ZhangHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Sean S BrummelHarvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-4116-404X
Paul K DrainDepartments of Global Health, Medicine, Pediatrics, and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9569-4097
Robert A SmithDepartments of Global Health, Medicine, Pediatrics, and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Geoffrey S GottliebDepartments of Global Health, Medicine, Pediatrics, and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-5749-481X
Lisa AbuogiDepartment of Pediatrics, University of Colorado, Denver, Colorado, USA.ORCID 0000-0003-1492-5090
Rena C PatelDepartments of Global Health, Medicine, Pediatrics, and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-9893-5856
Carey FarquharDepartments of Global Health, Medicine, Pediatrics, and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-8575-3439
Andrew WizniaNYC Health and Hospitals/Jacobi Medical Center, New York, New York, USA.ORCID 0000-0001-7487-1894
Theodore D RuelDivision of Pediatric Infectious Diseases and Global Health, University of California at San Francisco, San Francisco, California, USA.ORCID 0000-0002-1105-9126
Theresa M RossouwDepartment of Immunology, University of Pretoria, Pretoria, South Africa.ORCID 0000-0003-4066-922X
Stephen E HawesDepartments of Global Health, Medicine, Pediatrics, and Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-3361-6026
Lisa M FrenkelCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Funding
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypesR01AI147309 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI DRAIN, PAUL K, FRENKEL, LISA M · 2019 to 2023
$4.6M
Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids)R34MH115769 · NIMH · UNIVERSITY OF WASHINGTON · PI ABUOGI, LISA LYNN, PATEL, RENA CHIMAN · 2018 to 2019
$698k
AbbottBenke Family GiftBoehringer IngelheimGilead SciencesGlaxoSmithKlineIMPAACTIMPAACT Laboratory CenterIMPAACT Leadership and Operations Center UM1AI068616IMPAACT Statistical and Data Management Center UM1AI106716Molecular Profiling and Computational Biology Core of the UniversityNIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI147309NIAID NIH HHS T32 AI007509NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1AI068632NIAID NIH HHS UM1 AI106716NICHD NIH HHS HHSN275201800001CNICHD NIH HHS HHSN275201800001INIHNIMH NIH HHS R34 MH115769NIMH NIH HHS R34MH115769Seattle Children's Research InstituteThrasher Research Fund TRF15240University of PretoriaUniversity of Washington
6 · The paper itself
Abstract
We hypothesized that HIV-dolutegravir resistance is more frequent when coadministered with nucleos(t)ides with shorter intracellular half-lives. Multivariable analysis of 183 viremic (≥200 c/mL) participants from 4 cohorts (N = 660 participants) found dolutegravir resistance in 21 (11.5%). Dolutegravir resistance was greater with dolutegravir + lamivudine + zidovudine/(1 on stavudine) (odds ratio [OR] = 19.4, 95% confidence interval [CI]: 5.1-74.3) or dolutegravir + lamivudine +abacavir (OR = 5.4, 95% CI: 1.1-25.8), compared with dolutegravir + lamivudine + tenofovir.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
HIV Resistance to Dolutegravir Varies With Coadministered Agents. · full record | OpenQuestion